Patrick Campbell

A new pilot study assessing the shelf life of insulin when stored at room temperature during the summer in India suggests most insulins maintained 95% potency or greater at 4 months relative to refrigerated insulin.

An analysis of survey data from 500 patients with immune-mediated diseases, including rheumatoid arthritis, psoriasis, and IBD, suggests fewer than 1-in-4 patients were knowledgeable on the concept of biosimilars, but were open to learning more and considering use.

Leveraging data from more than 40,000 Veterans with primary hyperparathyroidism, a new NIA-funded study details the impact of parathyroidectomy on long-term kidney function among these patients.

A retrospective analysis of more than 60 patients 21 years or younger who received a transcatheter leadless pacemaker provides an overview of the safety of such an approach in younger patient populations.

A prospective study of more than 120 patients who underwent bariatric surgery sheds additional light on the potential benefits incurred by undergoing weight loss surgery in people with obesity.

The top 10 most popular FDA approval articles from the first quarter of 2023, with an additional spotlight on other top regulatory news from the first 3 months of the year.

A retrospective, propensity score-matched analysis details significant risk reductions achieved with bariatric surgery in patients with nonalcoholic fatty liver disease and obesity.

Announced on April 6, the recall, which is the most serious of its kind, includes all Readers used with the FreeStyle Libre, FreeStyle Libre 14 day, and FreeStyle Libre 2 Flash Glucose Monitoring Systems distributed from November 2017-February 2023, which totals more than 4 million devices in the US.

An analysis of data from patients in the DELIVER and DAPA-HF trials in the Americas provides an overview of the benefits of dapagliflozin in Black patients relative to White patients.

An analysis of more than 2 dozens studies provides and overview of the evolving safety profile of balloon pulmonary angioplasty in the treatment of chronic thromboembolic pulmonary hypertension in a period lasting from 2013-2022.

Leveraging data from the PADIT trial, investigators provide an overview of the impact of extent and timing of infections following cardiac implantable electronic device implantation.

Data from the ARCHITECT trial detail the effects of alirocumab use on coronary plaque burden and characteristics in a cohort of patients with familial hypercholesterolemia but without atherosclerotic cardiovascular disease.

Data from a recent study suggests statin-associated muscle symptoms were not exacerbated as a result of moderate-intensity physical activity.

An analysis of data from more than 10,000 individuals in Europe sheds new light on risk of arterial stiffness associated with excess sodium intake.

Data from the CLVer trial provide insight into the effects of verapamil use on beta cell function among a cohort of children and adolescents with newly diagnosed type 1 diabetes.

Our March 2023 cardiology month in review features top headlines from ACC.23, an approval for children with HoFH, and a feature celebrating the 10-year anniversary of the first SGLT2 inhibitor approval.

Our March 2023 endocrine month in review highlights the top news and headlines in endocrinology from the past month, including reductions in insulin list prices, regulatory decisions, and more!

The first study to examine joint effects of physical activity and sleep duration on mortality risk using accelerometry, results indicate increase activity could negate the effects of short or long sleep duration on cardiovascular and all-cause mortality.

Data from the PROMISE II study detail the effects of transcatheter arterialization procedures with the LimFlow System for reducing the rate of amputation in people with chronic limb-threatening ischemia.

An analysis of data from the St. Jude Lifetime Cohort Study provides new insight into the risk of long-term diastolic dysfunction associated with cardiotoxic cancer therapies in adult survivors of childhood cancer.

The latest scientific statement from the American Heart Association takes aim at offering clinicians with a summary of contemporary evidence related to the prevalence and increase in long-term risk associated with hypertension in children and adolescents.

This feature articles commemorates the 10-year anniversary of the FDA's first approval of an SGLT2 inhibitor on March 29, 2013 and provides a snapshot at the class's ascent into the treatment algorithms and guidelines for type 2 diabetes, heart failure, and chronic kidney disease.

The approval, which is for 4 mg naloxone hydrochloride nasal spray, marks the first OTC, nonprescription approval for a naloxone nasal spray and allows the product to be sold directly to consumers in a variety of retail locations well as online.

A silent disease characterized as a chronic cutaneous neuropathy, notalgia paresthetica has an unmet need yet to be fully understood and, dermatologists argue, an FDA-approved treatment could help improve understanding of the etiology and prevalence of this disease.

An analysis of more than 9000 adults aged 40 and older without known cardiovascular disease is shedding new light on the risk of myocardial infarction and mortality associated with subclinical coronary atherosclerosis.

A systematic review and meta-analysis of more than 120 randomized trials offers new insight into the effects of weight regain on cardiometabolic risk up to 5 years after the cessation of a behavioral management program.

On March 24, the US Food and Drug Administration announced a proposed rule changes aimed at promoting use of safe and suitable salt substitutes with the intent of improving nutrition and reducing chronic illness.

A phase 2 trial comparing once weekly basal insulin Fc against once daily insulin degludec, results of the study will help provide the basis for forthcoming phase 3 research examining the agent.

New research from the Family Heart Foundation indicates high-risk patients who fail to achieve LDL-C targets had a 49% greater rate of cardiovascular events than their counterparts who met LDL-C targets.

A 14-day randomized clinical trial assessing effects of caffeinated coffee consumption in a population of 100 adult patients, CRAVE offers what could be the most definitive insight yet into the effects of coffee consumption on overall health.